Welcome to our dedicated page for Mediwound news (Ticker: MDWD), a resource for investors and traders seeking the latest updates and insights on Mediwound stock.
MediWound Ltd (Nasdaq: MDWD) is a biopharmaceutical innovator developing enzymatic therapeutics for non-surgical wound care. This page provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and strategic developments.
Access consolidated information about NexoBrid adoption, EscharEx clinical trials, and pipeline progress. Stay informed about financial results, partnership announcements, and market expansion initiatives directly impacting MediWound's position in wound care innovation.
Key updates include FDA/EMA regulatory decisions, burn treatment protocols, chronic wound therapy breakthroughs, and peer-reviewed research findings. All content is verified through primary sources to ensure accuracy for investment and clinical decision-making.
Bookmark this page for streamlined access to MediWound's latest developments. Combine our updates with SEC filings and earnings call transcripts for comprehensive analysis of this enzymatic therapeutics leader.
MediWound Ltd. (Nasdaq: MDWD) announced the presentation of its EscharEx® clinical data at the 35th SAWC Spring Conference in April 2022. The oral presentation will cover results from clinical studies on the safety and efficacy of EscharEx for the debridement of hard-to-heal wounds, including venous leg ulcers and diabetic foot ulcers. The data showed that EscharEx was well-tolerated and effectively reduced biofilm and bacterial loads. The ongoing Phase 2 study aims to evaluate its clinical performance, positioning EscharEx as a potential non-surgical treatment for chronic wounds.
MediWound Ltd. (Nasdaq: MDWD) announced the partial exercise of an over-allotment option from its recent public offering, closing on March 22, 2022. The underwriter purchased an additional 623,082 ordinary shares, raising approximately $1.2 million. This brings the total funds raised in the offering to $11.2 million. MediWound plans to utilize the proceeds for working capital and corporate purposes. The offering was conducted under a previously filed shelf registration statement with the SEC.
MediWound Ltd. (Nasdaq: MDWD) has completed its U.S. Phase 2 clinical study of EscharEx for treating venous leg ulcers (VLUs). The study met its primary endpoint, showing a significant improvement in complete debridement rates: 63% for EscharEx versus 30% for the gel vehicle (p=0.004). Final results, including secondary safety measurements, are expected in Q2 2022. CEO Sharon Malka emphasized EscharEx's potential as a leading solution for chronic wound care, aiming to advance to pivotal Phase 3 trials.
MediWound Ltd. (MDWD) reported total revenues of $23.8 million for 2021, reflecting a 9% increase from 2020, with product revenues soaring 46% to $11.4 million. The company achieved profitability for its NexoBrid product but faced an 18% decline in Q4 revenues to $5.5 million. A public equity offering garnered an additional $10 million. Positive results from the Phase 2 EscharEx trial support its potential for chronic wound treatment, and FDA guidance indicates a path for the NexoBrid Biologics License Application resubmission in mid-2022.
MediWound Ltd. (Nasdaq: MDWD) announced the closure of its public offering of 5,208,333 ordinary shares at $1.92 per share, raising approximately $10 million. The underwriters received a 30-day option for an additional 781,249 shares. The funds will be used for working capital and corporate purposes. Notable investors include Clal Biotechnology Industries, the largest shareholder. This offering utilized a shelf registration statement declared effective by the SEC in April 2019.
MediWound Ltd. (Nasdaq: MDWD) will release its financial results for Q4 and the year ending December 31, 2021, on March 17, 2022. Following this, a conference call will take place at 8:30 AM ET, allowing management to discuss results and corporate updates. MediWound focuses on bio-therapeutic solutions for tissue repair, including NexoBrid®, a product for burn care, currently marketed in the EU and at the registration stage in the U.S., and EscharEx®, a topical treatment for chronic wounds. The company's strategy emphasizes innovation in improving patient care.
MediWound Ltd. (Nasdaq: MDWD) announced a public offering of 5,208,333 ordinary shares priced at $1.92 each, aiming for gross proceeds of approximately $10 million. All shares are being sold by the company, with closing expected around March 7, 2022. The funds will be allocated for working capital and general corporate purposes. Oppenheimer & Co. is the sole book-running manager. This offering is registered under Form F-3 with the SEC. MediWound specializes in bio-therapeutic solutions for tissue repair and regeneration, including its NexoBrid product for burn treatment.
MediWound Ltd. (Nasdaq: MDWD) announced plans for an underwritten public offering of its ordinary shares, all offered by the company itself, with underwriters receiving a 30-day option to buy an additional 15%. The offering will proceed under a previously filed shelf registration statement and is contingent on market conditions. Oppenheimer & Co. Inc. will manage the offering. Interested investors are advised to review the forthcoming preliminary prospectus supplement for comprehensive details regarding the securities offered.
MediWound Ltd. (Nasdaq: MDWD) announced its participation in two investor conferences in March 2022. The first event is Cowen’s 42nd Annual Health Care Conference on March 9 at 9:10 am ET, followed by Oppenheimer on March 17 at 11:20 am ET. Both presentations will emphasize MediWound’s focus on biotherapeutic solutions for tissue repair. NexoBrid®, their commercial product, treats severe burns efficiently, while EscharEx® is in development for chronic wound care. Replays of the events will be available on the MediWound Investor Relations website.
MediWound Ltd. (Nasdaq: MDWD) has been awarded a $1.7 million research project by the U.S. Department of Defense (DoD) through the Medical Technology Enterprise Consortium (MTEC) to develop NexoBrid as a non-surgical solution for burn treatment in field care. This funding recognizes NexoBrid's effectiveness for eschar removal and aims to improve treatment outcomes for U.S. Army service members suffering from traumatic burn injuries. The project is set to span 24 months and focuses on ensuring optimal care close to the point of injury.
FAQ
What is the current stock price of Mediwound (MDWD)?
What is the market cap of Mediwound (MDWD)?
